Disposition of Lasofoxifene, a Next-Generation Selective Estrogen Receptor Modulator, in Healthy Male Subjects

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Drug Metabolism And Disposition

• Publication date

  2008-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.108.020404PMID 18372400
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analytical strategies for identifying drug metabolites.

  2007cited by this paper
• Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.

  2007cited by this paper
• Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis

  2006cited by this paper
• Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.

  2004cited by this paper
• Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

  2003cited by this paper
• Pharmacokinetics of Selective Estrogen Receptor Modulators

  2003cited by this paper
• The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN

  2003cited by this paper
• Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN

  2003cited by this paper
• Review on raloxifene: profile of a selective estrogen receptor modulator.

  2003cited by this paper
• Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women.

  2003cited by this paper
• Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

  2003cited by this paper
• Estrogen plus progestin and the risk of coronary heart disease.

  2003cited by this paper
• Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Sex steroids and the construction and conservation of the adult skeleton.

  2002cited by this paper
• Postmenopausal osteoporosis management

  2000cited by this paper
• Role of quinones in toxicology.

  2000cited by this paper
• Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

  2000influential reference
• Raloxifene hydrochloride.

  2000cited by this paper
• Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.

  2000cited by this paper
• Pharmacokinetics of raloxifene and its clinical application.

  1999cited by this paper
• Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models.

  1998cited by this paper
• The Association of Urinary Incontinence with Poor Self‐Rated Health

  1998cited by this paper
• Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.

  1998influential reference
• Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.

  1998cited by this paper
• Optimal calcium intake.

  1995cited by this paper
• Influence of aging and menopause in determining vertebral and distal forearm bone loss in adult healthy women.

  1993cited by this paper
• Quinone chemistry and toxicity.

  1992cited by this paper
• Metabolism of exogenous 4- and 2-hydroxyestradiol in the human male.

  1986cited by this paper
• [Catechol estrogens].

  1984cited by this paper
• Metabolism of foreign compounds by gastrointestinal microorganisms.

  1973cited by this paper
• THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

  1964cited by this paper

• Comparison of estrogens and selective estrogen receptor modulators (SERMs) used for menopausal hormone therapy.

  2025cites this paper
• Phenoxyalkyl cyclic and acyclic amine derivatives: what do they teach us about scaffold-based drug design?

  2024cites this paper
• Special Section on Perspective on Drug Metabolism and Disposition, Part I — Minireview Human Absorption, Distribution, Metabolism, and Excretion Studies: Origins, Innovations, and Importance S

  2023cites this paper
• Absorption, disposition and metabolic pathway of amiselimod (MT-1303) in healthy volunteers in a mass balance study

  2019cites this paper
• Substrates of Human CYP2D6

  2018cites this paper
• Early Assessment of Exposure of Drug Metabolites in Humans Using Mass Spectrometry

  2014cites this paper
• Synthesis and Bioactivation of Selective Estrogen Receptor Modulators (SERMs)

  2013influential citation
• Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary

  2013cites this paper
• Selective estrogen receptor modulator (SERM) lasofoxifene forms reactive quinones similar to estradiol.

  2012cites this paper
• Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?

  2012cites this paper
• CYP450 Enzymes in Drug Discovery and Development: An Overview

  2012cites this paper
• Lasofoxifene: Selective Estrogen Receptor Modulator for the Prevention and Treatment of Postmenopausal Osteoporosis

  2011cites this paper
• Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

  2010cites this paper
• Human radiolabeled mass balance studies: objectives, utilities and limitations.

  2009cites this paper
• Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis

  2009cites this paper
• Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy

  2009cites this paper
• Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.

  2009cites this paper
• Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

  2009cites this paper
• New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme

  2009cites this paper
• “DMD #21808” 1 METABOLISM, DISTRIBUTION AND EXCRETION OF A NEXT GENERATION SELECTIVE ESTROGEN RECEPTOR MODULATOR, LASOFOXIFENE, IN RATS AND MONKEYS

  2008cites this paper
• Metabolism, Distribution, and Excretion of a Next Generation Selective Estrogen Receptor Modulator, Lasofoxifene, in Rats and Monkeys

  2008cites this paper
• Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.

  2007cites this paper
• Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin.

  2006cites this paper